ATLAS fair value
DKK 473.32
Below fair value · 45% discount
Novo Nordisk stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - General · Nasdaq Copenhagen · Denmark
Prices as of Oct 26, 2026 · DKK
DKK 473.32
Below fair value · 45% discount
50%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS estimates Novo Nordisk's fair value at about DKK 473.32 per share (reasonable range: DKK 301.93 to DKK 612.55). At DKK 260.45, the stock trades 45% below it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Novo Nordisk a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between DKK 245.56 and DKK 276.70; in 9 out of 10, between DKK 220.91 and DKK 307.58. Estimated annual volatility is 30%.
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Novo Nordisk sits below fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks NOVO-B.CO has traded between DKK 224.25 and DKK 409.95. Today it is 36.5% below that high and 16% above its low.
On the business: net margin is 35.4%; it trades at 9.8 times earnings.
Its beta is 0.38: it tends to move less than the market.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Want to see everything about Novo Nordisk?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
About DKK 473.32 per share according to ATLAS (reasonable range: DKK 301.93 to DKK 612.55). With the stock at DKK 260.45, it is 45% below it.
50%: close to a coin flip. In half of the simulated outcomes, NOVO-B.CO ends the month between DKK 245.56 and DKK 276.70.
Novo Nordisk's market capitalization is DKK 1.1T. Its price-to-earnings (P/E) ratio is 9.8: you pay DKK 9.75 for each DKK 1.00 of yearly earnings.
Yes. NOVO-B.CO's current dividend yield is 4.44% at today's price (DKK 260.45).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy